Quick Facts

• Chronic Stable Angina: Used to help manage symptoms of chronic stable angina pectoris (chest pain) in adults who are unable to take or whose condition is not adequately controlled by beta-blockers.
• Chronic Heart Failure: Indicated to support the management of chronic heart failure (NYHA Class II–IV) with systolic dysfunction, for patients in sinus rhythm with an elevated heart rate.

---

Бравадин (Ivabradine) is a prescription medication utilized in cardiovascular care. Its use is focused on two primary therapeutic domains, aimed at supporting patient well-being when a physician determines it is appropriate for their specific clinical situation.

One main use is to address the symptoms associated with chronic stable angina in adult patients. This may be especially relevant for individuals with certain contraindications to, or inadequate control from, standard beta-blocker therapy.

A second approved use is in the management of chronic heart failure in patients with New York Heart Association (NYHA) functional class II to IV symptoms. It is specifically intended for patients who have an elevated heart rate while remaining in sinus rhythm, and is used in combination with standard recommended therapy, including beta-blocker treatment, or when beta-blockers are not an option. Its mechanism of action assists in reducing the resting heart rate, which contributes to improved heart function in these specific patient populations.

Who Can and Cannot Use Бравадин (Ivabradine)?

Official regulatory documents define strict criteria for patient eligibility for Бравадин (Ivabradine). Use is generally restricted to adult patients (age 18 and over) in sinus rhythm with either chronic stable angina or chronic heart failure.

---

Classification	Eligibility Rules Based on Regulatory Labeling
Absolute Contraindications	Use is prohibited in patients with a pre-treatment resting heart rate below 60–70 bpm (depending on the region), severe hepatic impairment, sick sinus syndrome, or 3^rd degree AV block (unless pacemaker dependent).
Specific Exclusions	Must not be used in pregnancy or lactation, or in women of childbearing potential not using reliable contraception. Also contraindicated with strong CYP3A4 inhibitors and specific rate-reducing agents (e.g., diltiazem, verapamil).
Use Not Recommended	Not recommended for patients with severe renal impairment (creatinine clearance < 15 ml/min) due to insufficient data, or in the presence of atrial fibrillation or 2^nd degree AV block.
Age Limitations	Generally not established or not recommended for use in children under 18 years of age. Older adults (age 75 and over) require special consideration upon initiation.

---

These rules establish a highly specific user profile. For those approved, the medicine is intended for use when the patient's resting heart rate is ge 70 bpm and their condition is stable. The contraindications emphasize the drug's absolute exclusion in cases of significant electrical conduction defects or severe organ dysfunction.

Ivabradine is primarily metabolized in the liver and intestines by the cytochrome P450 3A4 (CYP3A4) enzyme. Therefore, its systemic exposure is significantly affected by co-administered medicines that inhibit or induce this enzyme, leading to major interaction risks.

Contraindicated Combinations

• Strong CYP3A4 inhibitors are strictly contraindicated due to their potential to substantially increase ivabradine plasma levels, resulting in a high risk of excessive heart rate slowing (bradycardia). This class includes certain azole antifungals (e.g., ketoconazole, itraconazole), macrolide antibiotics (e.g., clarithromycin), and HIV protease inhibitors (e.g., nelfinavir).
• Heart rate reducing calcium channel blockers such as verapamil and diltiazem are also contraindicated, as they are moderate CYP3A4 inhibitors and simultaneously potentiate the drug's heart rate lowering effect.

Combinations Requiring Caution or Avoidance

• Grapefruit products should be avoided due to their effect as moderate CYP3A4 inhibitors, which can increase ivabradine exposure.
• CYP3A4 inducers, including herbal products containing St. John's wort, should be avoided as they decrease ivabradine levels, potentially reducing its clinical effectiveness.
• Concomitant use with other negative chronotropes (agents that slow the heart rate), such as beta-blockers, amiodarone, or potent Class I anti-arrhythmics, requires careful heart rate monitoring due to the risk of an additive bradycardic effect.

Selective Inhibition of the Pacemaker Current

Бравадин acts as a highly selective inhibitor of the cardiac If current (funny current) within the sinoatrial node, the specialized tissue that governs the heart's rhythm. This action involves binding to and blocking the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. By inhibiting this specific electrical channel, the drug modifies the early molecular steps that determine the heart's spontaneous firing rate.

---

Chronotropic Modulation and Diastolic Prolongation

Inhibiting the If current slows the rate of spontaneous diastolic depolarization in the pacemaker cells, which directly reduces the frequency at which the heart's electrical signals are generated. This mechanism produces a negative chronotropic effect, resulting in a reduction in the firing frequency of the heart's pacing pathway. The selective slowing of the heart rate prolongs the diastole (the heart's relaxation and filling phase) without altering the force of heart muscle contractions or systemic blood pressure. This extended filling time results in a greater blood volume in the ventricles and a change in the heart's energetic demand.

Official Administration Guidelines

Бравадин (Ivabradine) is administered exclusively via the oral route in the form of film-coated tablets or an oral solution. The official use protocol requires a precise administration schedule and a structured titration process based on physiological response.

Entity	Instruction Details (Strictly Label-Based)
Route of administration	Oral (by mouth).
Dosing schedule	Standard starting dose: 5 mg twice daily (BID). Maximum dose: 7.5 mg twice daily.
Timing in relation to meals	Must be taken with meals (food).
Age-group rules	A lower starting dose of 2.5 mg BID may be considered for adults 75 years and older. Pediatric dosing (6 months and older) is weight-based.

The entire daily dose must be split and taken on a twice-daily frequency, ideally once in the morning and once in the evening, with a meal. Tablets are typically scored for dose flexibility, and oral solution must be measured with a calibrated syringe.

Resulting Procedural Structure

The most critical component of the official use protocol is the mandatory, structured dose adjustment. Treatment is initiated with the specified starting dose, followed by a reassessment of the resting heart rate (HR) after a minimum of two weeks. Subsequent dose adjustments must be made based on the measured HR, ensuring the dose remains within the approved minimum and maximum ranges. If a dose is missed, the protocol is to take the next dose at the usual time; a double dose should not be taken. For chronic stable angina, discontinuation is a documented consideration if symptoms show no improvement after three months of use.

Research Evidence / Overview of Studies for Бравадин (Ivabradine)

1. Evidence for use in Chronic Stable Angina Pectoris

Research for Ivabradine has primarily involved Randomized Controlled Trials (RCTs) and other studies observing how symptoms change over time in patients with stable angina. These studies monitored outcomes related to physical discomfort and daily functioning, such as measuring the weekly frequency of angina attacks and the consumption of short-acting nitrates, alongside objective measures of physiological strain.

Studies reported data related to measured changes in the frequency of angina episodes compared to a placebo. Research also examined changes in physical capability, such as the duration a patient could exercise before discomfort was noted. However, large-scale, long-term research examining major cardiovascular events, such as one key study (SIGNIFY), did not establish a pattern in the primary outcome of cardiovascular death or non-fatal heart attack. Research provides insight into short-term symptom patterns, but evidence describing major long-term events remains under investigation. The evidence describing the effect across all types of angina patients is still emerging.

2. Evidence for use in Chronic Heart Failure (Reduced Ejection Fraction)

The primary research exploring Ivabradine for chronic heart failure involves large-scale, international studies, most notably a major outcomes trial (SHIFT). These studies were structured as RCTs to monitor physiological strain or stress and compare outcomes against placebo. The main focus was on a combined primary measure: the time elapsed until the first event of either hospitalization for worsening heart failure or cardiovascular death occurred.

The primary trial reported patterns in the rate of the combined endpoint of CV death or hospitalization for worsening heart failure, as measured during the study period. Further analysis described that this pattern was mainly associated with a measured change in the frequency of hospitalizations for worsening heart failure. The trial did not establish a separate, statistically significant pattern for the individual outcome of mortality when analyzed alone. The most notable difference in outcomes was observed in a specific patient group: those with a higher starting heart rate (ge 77 beats per minute) and those who were not fully receiving the target dose of concurrent beta-blocker therapy. Data are still emerging regarding the degree of effect in patients who are already receiving the highest tolerated dose of beta-blockers, and certainty remains low for patients with a lower resting heart rate.

3. Research Gaps and Areas of Uncertainty

The research contributes to the broader evidence landscape but highlights areas where more data are needed. The major limitation is that the results apply only to the populations studied. Comparative evidence is lacking in some areas, as some studies did not directly compare Ivabradine to all available standard therapies. Overall, the evidence highlights what is known—and what is still uncertain—about this medicine.

Key Studies & References Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial)

Common questions about Бравадин (FAQ)

---

Q: What if I miss a dose of Bravadin?

If a dose is missed, official regulatory guidance indicates that the next dose should be taken at the usual time. Official information describes that taking a double dose is not recommended to compensate for the one missed, as this may increase the risk of side effects.

---

Q: Can Bravadin be used to treat children?

Official information states that the active ingredient in Bravadin is indicated for treating chronic heart failure in children who are six months of age and older. This applies to cases where heart failure is caused by an enlarged heart, known as dilated cardiomyopathy. Use in children younger than six months has not been established in regulatory documents.

---

Q: Should I keep taking Bravadin if I feel well?

Official patient materials state that stopping this medication suddenly is not advised and requires consulting with a healthcare provider, even if symptoms are controlled. Treatment is typically part of a long-term plan, and abrupt discontinuation may disrupt the management of your condition.

---

Q: Does Bravadin affect my ability to drive?

Official product information advises caution when driving or operating machinery. This is due to the potential for temporary visual side effects, such as luminous phenomena (flashes or halos), and the common occurrence of dizziness. Patients are advised to be aware of how the medicine affects them before engaging in these activities.

---

Q: Does Bravadin affect kidney function?

Studies on how the body handles Ivabradine indicate that the drug's systemic exposure is minimally affected by renal impairment in most cases. For the majority of patients with kidney issues, specific dose adjustments are generally not required. However, use is not recommended in cases of very severe renal impairment due to a lack of sufficient data.

---

Q: Can Bravadin be taken with dihydropyridine blood pressure medicines (e.g., Amlodipine)?

Regulatory prescribing information indicates that Ivabradine may be used in combination with dihydropyridine calcium channel blockers, such as Amlodipine. This combination may be considered when the symptoms of angina are not adequately controlled, and when other heart rate-reducing agents cannot be tolerated or are otherwise contraindicated.

---

Q: What symptoms indicate I should contact a doctor while taking Bravadin?

Regulatory documents state that symptoms such as a very slow, fast, or irregular heartbeat, dizziness, or fainting warrant immediate consultation with a healthcare provider. Furthermore, signs of a serious allergic reaction, such as swelling of the face, lips, or tongue, also require immediate attention.

---

Q: Does smoking or alcohol affect Bravadin?

While taking Ivabradine, official patient materials suggest consulting a healthcare provider before consuming alcohol. Regulatory documents provide specific warnings about certain food and herbal interactions, but the guidance concerning alcohol consumption requires professional consultation.

---

Q: Is there a risk of developing atrial fibrillation with Bravadin?

Atrial fibrillation (a form of irregular heartbeat) is listed as a common side effect of Ivabradine. This means that atrial fibrillation is noted as an identified risk associated with the medication. Regulatory guidance states that regular monitoring for the occurrence of atrial fibrillation is typically recommended.

---

Q: What should I do if my vision worsens while taking Bravadin?

If you notice temporary visual disturbances, such as luminous phenomena (flashes or halos), official patient materials suggest wearing sunglasses may help manage the symptoms. If the vision problems persist or worsen with changes in light, it is recommended that a healthcare provider be consulted.

---

Q: Does Bravadin affect cholesterol levels?

Official safety data reports that hypercholesterolemia, which is an increase in cholesterol levels, has been observed in some patients during clinical trials. This is noted as a metabolic condition observed during trials.

---

Q: Can Bravadin be taken with antibiotics?

It is stated that some specific types of antibiotics, particularly those in the macrolide class (for example, Clarithromycin), are strictly contraindicated. This is because these drugs can significantly increase the levels of Ivabradine in the blood. Patients should review all medications, including antibiotics, with their healthcare provider.

---

Q: What are the expectations for Bravadin—is it a complete cure or just symptom control?

The official uses of Ivabradine are described as the symptomatic treatment of chronic stable angina pectoris. Additionally, it is used to reduce the risk of hospitalization for worsening heart failure in specific patient groups. The purpose of the medicine focuses on managing symptoms and reducing disease-related events.

---

Q: Is Bravadin a long-term medication?

Clinical evidence supports the continuous and long-term administration of Ivabradine. Studies have assessed its safe use over periods of at least 12 months, which is consistent with its role in the chronic management of stable heart conditions.

---

Q: What other medicines can interact with Bravadin?

In addition to those strictly contraindicated, regulatory labels mention other medicines that may interact. These include CYP3A4 inducers (such as the herbal product St. John's wort), which can decrease the drug's effectiveness. Caution is also advised when combining it with other agents that slow the heart rate (negative chronotropes).

---

Q: What happens if I take Bravadin on an empty stomach?

Official documents describe that Ivabradine must be taken with meals. Food has been shown to delay the drug’s absorption and increase the body's overall exposure to the medication by 20% to 40% compared to taking it in a fasting state. This timing is necessary to achieve the desired effect.

---

Q: What are the special warnings for Bravadin in patients with severe heart failure?

Ivabradine is explicitly contraindicated in patients who have decompensated (unstable) heart failure. Official documents stress that its use is only indicated for stable heart failure with a reduced ejection fraction, and only when specific heart rate criteria are met.

---

Q: Is there a special diet to follow while taking Bravadin?

Regulatory information specifically advises patients not to consume grapefruit or grapefruit juice during treatment. This is because grapefruit can increase the level of Ivabradine in the blood, potentially raising the risk of side effects.

---

Q: Does Bravadin increase the risk of blood pressure problems?

Official data lists increased blood pressure, or hypertension, as a common side effect observed in clinical trials. This means that this effect was reported in 1 to 10 out of every 100 patients studied.

---

Q: Is there information on Bravadin use in retinitis pigmentosa?

Prescribing cautions for Ivabradine specifically mention that the drug should be used with caution in patients who have retinitis pigmentosa. This is a progressive genetic eye disease, and this caution is linked to the drug's known ocular side effects.

---

Q: What is the main difference between Bravadin and other pulse-lowering drugs?

Ivabradine is classified as a highly selective inhibitor of the If current, which is a specialized electrical flow in the heart. This unique mechanism allows it to reduce heart rate without the negative inotropic effects (changes to the force of heart muscle contraction) or significant blood pressure lowering typically seen with beta-blockers.

---

Q: Is any special monitoring required before starting Bravadin?

Official patient guidance advises that patients should expect to undergo an ECG (electrocardiogram) before beginning treatment with this medication. This test helps ensure that the heart rhythm meets the necessary criteria for initiating the drug.

How to Store and Dispose of Ivabradine (Бравадин)

Official regulatory documents define strict conditions for the storage and disposal of Ivabradine (Bravadin) tablets to ensure stability and proper handling.

Storage Requirements

Item	Official Requirement
Temperature	Store below 30 C (controlled room temperature).
Protection	Must be kept in the original container, protected from light and moisture.
Child Safety	Must be stored out of the sight and out of the reach of children.

The medicine should not be used after the expiration date printed on the packaging. Stability is maintained when the product is stored under these conditions in its original container.

Disposal Instructions

Unused or expired Ivabradine must not be thrown into household trash or flushed down the toilet or sink. Disposal must be conducted according to local environmental regulations, typically by returning the product to a pharmacy or designated pharmaceutical collection point.